United Therapeutics Acquires Pfizer Royalty Interest in Experimental Lung Therapy Ralinepag
United Therapeutics (UTHR) announced the acquisition of Pfizer's (PFE) royalty interest related to ralinepag, an experimental therapy designed to treat lung disease. The announcement coincided with the company's release of its third-quarter 2026 financial results. Following the news, United Therapeutics shares saw upward movement in premarket trading. This strategic acquisition allows United Therapeutics to capture a larger share of future revenue from the development and potential commercialization of ralinepag.
